Article
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Cancer research - 1 Nov 2007
Yu Zhiwei, Boggon Titus J, Kobayashi Susumu, Jin Cheng, Ma Patrick C, Dowlati Afshin, Kern Jeffrey A, Tenen Daniel G, Halmos Balázs
Abstract excerpt
Patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer derive significant clinical benefit from treatment with the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Secondary EGFR mutations such as EGFR T790M commonly lead to resistance to these agents, lim...
Topics
- Cell Line, Tumor
- Cyclin-Dependent Kinase 4
- Drug Resistance, Neoplasm
- ErbB Receptors
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Quinazolines
- Structure-Activity Relationship